FibroGen Statistics
Total Valuation
FibroGen has a market cap or net worth of $44.48 million. The enterprise value is $114.25 million.
Important Dates
The last earnings date was Monday, November 3, 2025, after market close.
| Earnings Date | Nov 3, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
FibroGen has 4.04 million shares outstanding. The number of shares has increased by 1.97% in one year.
| Current Share Class | 4.04M |
| Shares Outstanding | 4.04M |
| Shares Change (YoY) | +1.97% |
| Shares Change (QoQ) | +0.10% |
| Owned by Insiders (%) | 1.97% |
| Owned by Institutions (%) | 15.59% |
| Float | 3.63M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.04 |
| Forward PS | 6.90 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 15.55 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.04
| Current Ratio | 1.04 |
| Quick Ratio | 0.15 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7.23 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -16.40% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -278.99% |
| Revenue Per Employee | $32,649 |
| Profits Per Employee | -$9,182 |
| Employee Count | 225 |
| Asset Turnover | 0.03 |
| Inventory Turnover | 2.48 |
Taxes
| Income Tax | -85,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +43.32% in the last 52 weeks. The beta is 0.74, so FibroGen's price volatility has been lower than the market average.
| Beta (5Y) | 0.74 |
| 52-Week Price Change | +43.32% |
| 50-Day Moving Average | 11.42 |
| 200-Day Moving Average | 9.41 |
| Relative Strength Index (RSI) | 48.63 |
| Average Volume (20 Days) | 20,092 |
Short Selling Information
The latest short interest is 104,727, so 2.59% of the outstanding shares have been sold short.
| Short Interest | 104,727 |
| Short Previous Month | 112,039 |
| Short % of Shares Out | 2.59% |
| Short % of Float | 2.89% |
| Short Ratio (days to cover) | 3.64 |
Income Statement
In the last 12 months, FibroGen had revenue of $7.35 million and -$2.07 million in losses. Loss per share was -$0.51.
| Revenue | 7.35M |
| Gross Profit | -28.95M |
| Operating Income | -61.83M |
| Pretax Income | -87.49M |
| Net Income | -2.07M |
| EBITDA | -60.19M |
| EBIT | -61.83M |
| Loss Per Share | -$0.51 |
Full Income StatementBalance Sheet
The company has $23.37 million in cash and $93.13 million in debt, giving a net cash position of -$69.76 million or -$17.25 per share.
| Cash & Cash Equivalents | 23.37M |
| Total Debt | 93.13M |
| Net Cash | -69.76M |
| Net Cash Per Share | -$17.25 |
| Equity (Book Value) | -181.03M |
| Book Value Per Share | -55.14 |
| Working Capital | 6.43M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$23.44 million and capital expenditures -$252,000, giving a free cash flow of -$23.69 million.
| Operating Cash Flow | -23.44M |
| Capital Expenditures | -252,000 |
| Free Cash Flow | -23.69M |
| FCF Per Share | -$5.86 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -841.61% |
| Pretax Margin | -1,191.00% |
| Profit Margin | -28.12% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FibroGen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.97% |
| Shareholder Yield | -1.97% |
| Earnings Yield | -4.64% |
| FCF Yield | -53.26% |
Analyst Forecast
The average price target for FibroGen is $146.50, which is 1,231.82% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $146.50 |
| Price Target Difference | 1,231.82% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | -30.69% |
| EPS Growth Forecast (5Y) | -7.84% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 17, 2025. It was a reverse split with a ratio of 1:25.
| Last Split Date | Jun 17, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
FibroGen has an Altman Z-Score of -15.87 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -15.87 |
| Piotroski F-Score | 1 |
